Novel nano-biomaterials for inhibition of respiratory syncytial virus

Sameer Joshi, Daniel Kirby, Yvonne Perrie, Shree R. Singh

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

Respiratory syncytial virus (RSV) infection is a major concern for the population across all age groups and it is the single serotype with two major antigenic subgroups circulating together but one leads [1]. Considering published outcomes related to treatment, as well as the impact of RSV on global healthcare, a promising treatment or vaccine development remains a priority. The potential of liposomes as a carrier of active pharmacological agents was described decades ago [2-4] whilst liposomes have attracted much attention for their ability to carry antigens as well as immunomodulators [5]. Therefore, the work in this paper was aimed to prepare liposomes < 100 nm using thin film hydration followed by sonication, to effectively conjugate the anti-RSV peptide RF-482 and investigate the efficiency the liposomal formulation in presence and absence peptide RF-482 to inhibit RSV spread.

Original languageEnglish
Title of host publicationBiotech, Biomaterials and Biomedical - TechConnect Briefs 2017
Pages75-78
Number of pages4
Volume3
ISBN (Electronic)9780998878201
Publication statusPublished - 1 Jan 2017
Event11th Annual TechConnect World Innovation Conference and Expo, Held Jointly with the 20th Annual Nanotech Conference and Expo, and the 2017 National SBIR/STTR Conference - Washington, United States
Duration: 14 May 201717 May 2017

Conference

Conference11th Annual TechConnect World Innovation Conference and Expo, Held Jointly with the 20th Annual Nanotech Conference and Expo, and the 2017 National SBIR/STTR Conference
CountryUnited States
CityWashington
Period14/05/1717/05/17

Fingerprint

Respiratory Syncytial Viruses
Biocompatible Materials
Viruses
Biomaterials
Liposomes
Peptides
Respiratory Syncytial Virus Infections
Sonication
Immunologic Factors
Vaccines
Antigens
Age Groups
Hydration
Pharmacology
Delivery of Health Care
Therapeutics
Thin films
Population

Bibliographical note

© 2017 TechConnect.

Keywords

  • Liposomes
  • Peptide
  • RSV

Cite this

Joshi, S., Kirby, D., Perrie, Y., & Singh, S. R. (2017). Novel nano-biomaterials for inhibition of respiratory syncytial virus. In Biotech, Biomaterials and Biomedical - TechConnect Briefs 2017 (Vol. 3, pp. 75-78)
Joshi, Sameer ; Kirby, Daniel ; Perrie, Yvonne ; Singh, Shree R. / Novel nano-biomaterials for inhibition of respiratory syncytial virus. Biotech, Biomaterials and Biomedical - TechConnect Briefs 2017. Vol. 3 2017. pp. 75-78
@inproceedings{c93dac43ad3a44ba89a491d930118b2c,
title = "Novel nano-biomaterials for inhibition of respiratory syncytial virus",
abstract = "Respiratory syncytial virus (RSV) infection is a major concern for the population across all age groups and it is the single serotype with two major antigenic subgroups circulating together but one leads [1]. Considering published outcomes related to treatment, as well as the impact of RSV on global healthcare, a promising treatment or vaccine development remains a priority. The potential of liposomes as a carrier of active pharmacological agents was described decades ago [2-4] whilst liposomes have attracted much attention for their ability to carry antigens as well as immunomodulators [5]. Therefore, the work in this paper was aimed to prepare liposomes < 100 nm using thin film hydration followed by sonication, to effectively conjugate the anti-RSV peptide RF-482 and investigate the efficiency the liposomal formulation in presence and absence peptide RF-482 to inhibit RSV spread.",
keywords = "Liposomes, Peptide, RSV",
author = "Sameer Joshi and Daniel Kirby and Yvonne Perrie and Singh, {Shree R.}",
note = "{\circledC} 2017 TechConnect.",
year = "2017",
month = "1",
day = "1",
language = "English",
volume = "3",
pages = "75--78",
booktitle = "Biotech, Biomaterials and Biomedical - TechConnect Briefs 2017",

}

Joshi, S, Kirby, D, Perrie, Y & Singh, SR 2017, Novel nano-biomaterials for inhibition of respiratory syncytial virus. in Biotech, Biomaterials and Biomedical - TechConnect Briefs 2017. vol. 3, pp. 75-78, 11th Annual TechConnect World Innovation Conference and Expo, Held Jointly with the 20th Annual Nanotech Conference and Expo, and the 2017 National SBIR/STTR Conference, Washington, United States, 14/05/17.

Novel nano-biomaterials for inhibition of respiratory syncytial virus. / Joshi, Sameer; Kirby, Daniel; Perrie, Yvonne; Singh, Shree R.

Biotech, Biomaterials and Biomedical - TechConnect Briefs 2017. Vol. 3 2017. p. 75-78.

Research output: Chapter in Book/Report/Conference proceedingConference contribution

TY - GEN

T1 - Novel nano-biomaterials for inhibition of respiratory syncytial virus

AU - Joshi, Sameer

AU - Kirby, Daniel

AU - Perrie, Yvonne

AU - Singh, Shree R.

N1 - © 2017 TechConnect.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Respiratory syncytial virus (RSV) infection is a major concern for the population across all age groups and it is the single serotype with two major antigenic subgroups circulating together but one leads [1]. Considering published outcomes related to treatment, as well as the impact of RSV on global healthcare, a promising treatment or vaccine development remains a priority. The potential of liposomes as a carrier of active pharmacological agents was described decades ago [2-4] whilst liposomes have attracted much attention for their ability to carry antigens as well as immunomodulators [5]. Therefore, the work in this paper was aimed to prepare liposomes < 100 nm using thin film hydration followed by sonication, to effectively conjugate the anti-RSV peptide RF-482 and investigate the efficiency the liposomal formulation in presence and absence peptide RF-482 to inhibit RSV spread.

AB - Respiratory syncytial virus (RSV) infection is a major concern for the population across all age groups and it is the single serotype with two major antigenic subgroups circulating together but one leads [1]. Considering published outcomes related to treatment, as well as the impact of RSV on global healthcare, a promising treatment or vaccine development remains a priority. The potential of liposomes as a carrier of active pharmacological agents was described decades ago [2-4] whilst liposomes have attracted much attention for their ability to carry antigens as well as immunomodulators [5]. Therefore, the work in this paper was aimed to prepare liposomes < 100 nm using thin film hydration followed by sonication, to effectively conjugate the anti-RSV peptide RF-482 and investigate the efficiency the liposomal formulation in presence and absence peptide RF-482 to inhibit RSV spread.

KW - Liposomes

KW - Peptide

KW - RSV

UR - http://www.scopus.com/inward/record.url?scp=85029358389&partnerID=8YFLogxK

UR - https://www.techconnect.org/proceedings/paper.html?volume=TCB2017v3&chapter=3&paper=193

M3 - Conference contribution

VL - 3

SP - 75

EP - 78

BT - Biotech, Biomaterials and Biomedical - TechConnect Briefs 2017

ER -

Joshi S, Kirby D, Perrie Y, Singh SR. Novel nano-biomaterials for inhibition of respiratory syncytial virus. In Biotech, Biomaterials and Biomedical - TechConnect Briefs 2017. Vol. 3. 2017. p. 75-78